Approval comes one month after advisors backed expanded indication
WASHINGTON -- Icosapent ethyl, the prescription fish-oil product sold as Vascepa, may now be marketed for reducing risk of cardiovascular events in adults with triglyceride levels of 150 mg/dL or higher, the FDA said late Friday.